TY  - GEN 
AU  - Mahlangu, Johnny
AU  - López Fernández, María Fernanda
AU  - Santagostino, Elena
AU  - Lalezari, Shadan
AU  - Tseneklidou-Stoeter, Despina
AU  - Beckmann, Horst
AU  - Church, Nikki
PY  - 2020
SN  - 0902-4441
UR  - http://hdl.handle.net/20.500.11940/16205
AB  - OBJECTIVES: BAY 81-8973 (Kovaltry((R)) ), a full-length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1-year LEOPOLD I trial. The LEOPOLD I extension evaluated long-term...
KW  - Adult
KW  - Hemophilia A
KW  - Middle Aged
KW  - Adolescent
KW  - Severity of Illness Index
KW  - Hemarthrosis
KW  - Quality of Life
KW  - Clinical Trial
KW  - Humans
KW  - Treatment Outcome
KW  - Factor VIII
KW  - Young Adult
KW  - Recombinant Proteins
KW  - Aged
TI  - BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ?2 years
DO  - 10.1111/ejh.13402
KW  - CHUAC
KW  - INIBIC
VL  - 104
ER  -